Hepatocyte-like Cells via Transcription Factor Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an unlimited source of human hepatocytes or hepatocyte-like cells for liver function improvement and disease treatment, as current methods like liver transplantation are limited by organ availability and immunosuppression requirements, and primary human hepatocytes are scarce and difficult to expand in vitro.
Innovation Solution
A method involving the expression of heterologous Hnf, Foxa, and GATA4 polypeptides in starting cells, such as fibroblasts, to generate hepatocyte-like cells, which can be cultured to exhibit hepatic functions and expanded for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary human hepatocytes are used for liver function improvement and disease treatment, then therapeutic effectiveness is improved, but cell availability is limited and expansion capability is poor
Solution Approach 1:
The patent creates hepatocyte-like cells by transdifferentiating non-hepatocyte cells (such as fibroblasts) through overexpression of hepatic transcription factors (HNF1α, HNF4α, FOXA3, GATA4). This copying approach generates functional hepatocyte substitutes that can be cultured and expanded indefinitely, overcoming the scarcity of primary human hepatocytes while maintaining therapeutic relevance
Solution Approach 2:
The patent changes the cellular parameters by inducing specific transcription factor expression patterns in non-hepatocyte cells. By controlling the expression levels and combinations of transcription factors (e.g., HNF1α, HNF4α, FOXA3, GATA4), the cells are reprogrammed to adopt hepatocyte-like phenotype and function, enabling unlimited expansion while preserving therapeutic effectiveness
2Reliability
If primary human hepatocytes are used for therapeutic purposes, then functional performance is improved, but in vitro expansion capability deteriorates
Solution Approach 1:
Instead of trying to expand primary hepatocytes directly (which is impossible), the patent inverts the approach by first creating a non-hepatocyte cell line (such as fibroblast) that can be easily expanded in vitro, then inducing hepatic differentiation in this expandable cell line through transcription factor overexpression. This inversion enables both unlimited expansion and functional performance
3Reliability
If liver transplantation is used to treat liver disorders, then therapeutic effectiveness is improved, but organ availability is limited and immunosuppression is required
Solution Approach 1:
The patent creates functional copies of hepatocytes from non-hepatocyte cells through transdifferentiation. These hepatocyte-like cells can be produced in unlimited quantities from readily available cell sources (fibroblasts, epithelial cells, blood cells), eliminating the organ shortage problem while maintaining liver function and offering avoidance of immunosuppression requirements
4Productivity
If hepatocyte-like cells are generated through transdifferentiation, then cell expansion capability is improved, but cellular identity accuracy may worsen
Solution Approach 1:
The patent precisely controls the transcription factor expression parameters (HNF1α, HNF4α, FOXA3, GATA4) to achieve accurate hepatocyte-like differentiation. By optimizing the combination, concentration, and timing of these transcription factors, the generated cells achieve both unlimited expansion capability and high cellular identity accuracy, expressing authentic hepatocyte markers and functions
Data Source
AI summary
The present invention relates to hepatocyte-like cells. Also disclosed are methods of making the cells and using the cells.